Company Overview and News

13
Burcon Announces Fiscal 2018 Results and Reviews Operations

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU), a leader in natural product extraction, purification and isolation technologies, reported results for the year ended March 31, 2018.
BUROF BUR BU

13
Burcon’s Peazazz and Peazac Pea Proteins Receive Self-Affirmed GRAS Status

2018-06-18 globenewswire
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (“Burcon” or the “Company”) a leader in natural product extraction, purification and isolation technologies, is pleased to announce the Company’s Peazazz® and Peazac® pea proteins have received self-affirmed Generally Recognized As Safe (GRAS) status, and the Company has officially submitted to the United States Food and Drug Administration (“FDA”) a formal GRAS Notification dossier.
BUROF BUR BU

14
Burcon Announces Delisting From Nasdaq Capital Market

2018-04-25 globenewswire
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX:BU) (NASDAQ:BUR) (“Burcon” or the “Company”), a leader in natural product extraction, purification and isolation technologies, announced today that it received a letter, dated April 25, 2018, from the Nasdaq Hearings Panel (the “Panel”) of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that the Panel has determined to delist the Company’s common shares from the Nasdaq Capital Market and will suspend trading in the shares effective at the open of business on April 27, 2018.
BUR OTCM BU

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

20h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

21h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to TSX:BU / Burcon Nutrascience Corp on message board site Silicon Investor.

Buy and Sell Signals, and Other Market Perspectives TNRG Tianrong Building Materials
Sudbury Saturday Night -- Nickel Mining u0026 Nickel Prices Silver Bull Resources, Inc.
BuSab RedHat Linux distributor -- IPO
NNVC - NanoViricides, Inc. (Bulls Board) The New QUALCOMM - Coming Into Buy Range
Buffettology PEP -- Time to buy?